BLISSGVS

Bliss GVS Pharma Share Price

 

 

Invest in Bliss GVS Pharma with 2.46X leverage

Invest with MTF

Performance

  • Low
  • ₹165
  • High
  • ₹176
  • 52 Week Low
  • ₹108
  • 52 Week High
  • ₹191
  • Open Price₹174
  • Previous Close₹176
  • Volume1,175,834

Investment Returns

  • Over 1 Month -3.3%
  • Over 3 Month + 12.95%
  • Over 6 Month + 11.71%
  • Over 1 Year + 4.26%

Smart Investing Starts Here Start SIP with Bliss GVS Pharma for Steady Growth!

Invest Now

Bliss GVS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 16.1
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 1,764
  • P/B Ratio
  • 1.6
  • Average True Range
  • 9.64
  • EPS
  • 10.36
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 1.01
  • RSI
  • 54.01
  • MFI
  • 85.79

Bliss GVS Pharma Financials

Bliss GVS Pharma Technicals

EMA & SMA

Current Price
₹166.73
-9.19 (-5.22%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹162.19
  • 50 Day
  • ₹159.28
  • 100 Day
  • ₹156.53
  • 200 Day
  • ₹150.85

Resistance and Support

169.3 Pivot Speed
  • R3 183.59
  • R2 179.68
  • R1 173.21
  • S1 162.83
  • S2 158.92
  • S3 152.45

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bliss GVS Pharma manufactures and exports pharmaceutical products, specializing in suppositories, pessaries, and oral medications. With a global presence in over 60 countries, it serves therapeutic segments like anti-malarial, antibiotics, and dermatology through its state-of-the-art facilities.

Bliss Gvs Pharma has an operating revenue of Rs. 860.27 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 16% is great, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 20% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 7% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 76 which is a FAIR score but needs to improve its earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 51 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bliss GVS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-06 Quarterly Results
2025-07-29 Quarterly Results
2025-05-12 Audited Results & Final Dividend
2025-01-28 Quarterly Results & Others To consider other business matters. per share(50%)Final Dividend
2024-10-24 Quarterly Results
Date Purpose Remarks
2025-07-24 FINAL Rs.0.50 per share(50%)Final Dividend
View Bliss GVS Pharma Dividend History Arrow

Bliss GVS Pharma F&O

Bliss GVS Pharma Shareholding Pattern

35.39%
0%
5.98%
13.27%
32.85%
12.51%

About Bliss GVS Pharma

  • NSE Symbol
  • BLISSGVS
  • BSE Symbol
  • 506197
  • Managing Director
  • Mr. Gagan Harsh Sharma
  • ISIN
  • INE416D01022

Similar Stocks to Bliss GVS Pharma

Bliss GVS Pharma FAQs

Bliss GVS Pharma share price is ₹166 As on 27 December, 2025 | 00:57

The Market Cap of Bliss GVS Pharma is ₹1763.8 Cr As on 27 December, 2025 | 00:57

The P/E ratio of Bliss GVS Pharma is 16.1 As on 27 December, 2025 | 00:57

The PB ratio of Bliss GVS Pharma is 1.6 As on 27 December, 2025 | 00:57

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23